OmniAb Investor Presentation Deck

Performance Indicators ACTIVE CLINICAL PROGRAMS AND APPROVED PRODUCTS ● ● New program entered the clinic in Q1 2023 SGN-BB228 (Seagen): Anti-CD228 x 4-1BB Anticalin Based on dialog with partners, we see potential for approximately 3-5 new entries into clinical development for novel OmniAb-derived antibodies in 2023 • Partner progression also showing the flexibility of our platform, with an increasing number of formats and modalities in clinical or preclinical development 30 25 20 15 10 5 0 2016 Number of Active Clinical Programs and Approved Products 2017 2018 2019 2020 2021 2022 3/31/2023 9 OmniAb

View entire presentation